This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dynavax: The BioRunUp Trade Into An FDA Panel

NEW YORK ( TheStreet) -- BioRunUp trading is a form of swing trading designed to capitalize on biotech share price volatility that almost always takes place around widely known catalysts like FDA drug approvals and clinical trial results.

Explained simply, Biorunup trading involves first identifying a date (or date range) on which an important biotech stock event is expected to take place, then positioning trades (equities and options both work) to capture profits as share prices inevitably "run up" into the chosen event.

The most profitable BioRunUp trades usually involve FDA drug approval decision dates. These are often referred to in jargon shorthand as "PDUFA dates" for the Prescription Drug User Fee Act that sets the rules and timelines by which FDA reviews and approves new drug applications.

FDA-appointed PDUFA dates are a gift to BioRunUp traders. History shows that biotech share prices almost always rise -- "run up" -- as the FDA approval decision date nears because investors and traders place their bets on approval and the resulting benefits to the company. As the PDUFA date draws close, this increased trading activity can snowball as momentum, technical and day traders get involved, thus increasing the share price even more.

BioRunUp traders like myself try to stay well ahead of the pack when it comes to playing PDUFA dates, which are typically known six to 10 months in advance depending on the length of the FDA review. Paying attention to PDUFA dates well in advance allows for early entry into a trade and the opportunity to hold a long position in a stock for one to three months prior to the event. The goal of the BioRunUp trade is to profit from the increased visibility and trading activity that typically shines on a biotech stock prior to the actual FDA drug approval decision being announced.

If there is one cardinal rule in BioRunUp investing, it is this: Never hold a biotech stock trade through the FDA drug approval decision. Let me be extra clear, the goal of BioRunUp investing is to trade and book profits before the event occurs. I am not in the business of trying to predict if the FDA will approve or reject a drug. I leave that work to others.

[What goes up, must come down so swing trading in biotech stock does work in the opposite direction as well, but I'll leave discussion about "BioRunDown" trading for a future column.]

Let's put the BioRunUp trading strategy into action. Dynavax (DVAX - Get Report) is seeking FDA approval for Heplisav, a vaccine to protect against hepatitis B infection in adults age 18-70. The assigned PDUFA date is Feb. 24th, 2013. While I consider this Dynavax PDUFA catalyst too far out on the calendar to trade effectively now, the FDA has also scheduled an advisory panel to review Heplisav on Nov. 14. This bumps Dynavax's tradable catalyst up by three months, and sets it up for a nice run up over the next two months.

Dynavax has a large cash position after completing a substantial share offering this May at $4.25 per share. The company's current share price is below the offering price. This financing should alleviate concerns over the possibility of dilution before the FDA advisory panel. [Biotech companies often take advantage of stock price run ups to bolster their cash reserves.]
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DVAX $17.53 0.00%
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs